FOOTHILL
RANCH, Calif., May 16, 2022
/PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global
leader in dental lasers, today announced that it has been invited
to present at the Spring Into Action Best Ideas Virtual Investor
Conference being held May 17-20,
2022. John Beaver, President
and Chief Executive Officer, will present at the conference and
host virtual one-on-one meetings with institutional investors and
analysts throughout the event.
BIOLASE is scheduled to present on Tuesday, May 17, 2022 at 1:00 pm PT (4:00 pm
ET). Management will be available for one-on-one meetings
May 19-20, 2022. The presentation
will be webcast live and available for replay at the investor
relations section of BIOLASE's website at www.biolase.com.
To receive additional information, request an invitation, or to
schedule a one-on-one meeting, please email
angie.wright@issuerdirect.com.
Investor can register here for the conference.
About BIOLASE
BIOLASE is a medical device company that develops,
manufactures, markets, and sells laser systems in dentistry and
medicine. BIOLASE's products advance the practice of dentistry and
medicine for patients and healthcare professionals. BIOLASE's
proprietary laser products incorporate approximately 301 patented
and 32 patent-pending technologies designed to provide biologically
and clinically superior performance with less pain and faster
recovery times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 43,300 laser systems
to date in over 80 countries around the world. Laser products under
development address BIOLASE's core dental market and other adjacent
medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase
Express™, and laser dentistry, find BIOLASE online
at www.biolase.com, Facebook at www.facebook.com/biolase,
Twitter at www.twitter.com/biolaseinc, Instagram
at www.instagram.com/waterlase_laserdentistry, and LinkedIn
at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements
regarding the anticipated roll out of new go-to-market sales
strategies, the Company's efforts to achieve its goal of becoming
EBITDA positive. Forward-looking statements can be identified
through the use of words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," "may,"
"will," "should," and variations of these words or similar
expressions. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE's current
expectations and speak only as of the date of this release. Actual
results may differ materially from BIOLASE's current expectations
depending upon a number of factors. These factors include,
among others, adverse changes in general economic and market
conditions, competitive factors including but not limited to
pricing pressures and new product introductions, uncertainty of
customer acceptance of new product offerings and market changes,
risks associated with managing the growth of the business, and
those other risks and uncertainties that are described, from
time-to-time, in the "Risk Factors" section of BIOLASE's annual
reports filed on Form 10-K with the Securities and Exchange
Commission. Except as required by law, BIOLASE does not undertake
any responsibility to revise or update any forward-looking
statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolase-to-participate-in-the-spring-into-action-best-ideas-virtual-investor-conference-may-17-20-2022-301547782.html
SOURCE BIOLASE, Inc.